JW Shinyak Past Earnings Performance
Past criteria checks 0/6
JW Shinyak's earnings have been declining at an average annual rate of -43.8%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 1.7% per year.
Key information
-43.8%
Earnings growth rate
-43.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 1.7% |
| Return on equity | -227.4% |
| Net Margin | -35.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is JW Shinyak (KOSDAQ:067290) A Risky Investment?
Mar 04
Factors Income Investors Should Consider Before Adding JW Shinyak Corporation (KOSDAQ:067290) To Their Portfolio
Jan 28Don't Race Out To Buy JW Shinyak Corporation (KOSDAQ:067290) Just Because It's Going Ex-Dividend
Dec 24
What Type Of Returns Would JW Shinyak's(KOSDAQ:067290) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Dec 07Revenue & Expenses BreakdownBeta
How JW Shinyak makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 104,235 | -37,357 | 37,670 | 2,904 |
| 30 Sep 23 | 107,086 | -36,223 | 38,347 | 2,877 |
| 30 Jun 23 | 105,604 | -37,104 | 38,951 | 2,733 |
| 31 Mar 23 | 102,661 | 684 | 38,420 | 2,538 |
| 31 Dec 22 | 102,710 | 1,400 | 38,119 | 2,612 |
| 30 Sep 22 | 101,568 | 1,715 | 38,015 | 2,262 |
| 30 Jun 22 | 101,300 | 2,528 | 36,935 | 2,700 |
| 31 Mar 22 | 101,868 | 2,580 | 37,730 | 2,880 |
| 31 Dec 21 | 100,966 | 884 | 37,674 | 3,134 |
| 30 Sep 21 | 99,208 | -3,111 | 38,393 | 3,678 |
| 30 Jun 21 | 102,190 | -3,344 | 39,543 | 2,950 |
| 31 Mar 21 | 104,121 | -2,837 | 39,261 | 2,849 |
| 31 Dec 20 | 103,803 | -6,446 | 39,818 | 2,593 |
| 30 Sep 20 | 106,035 | -2,482 | 41,568 | 2,001 |
| 30 Jun 20 | 104,066 | -1,637 | 41,505 | 2,198 |
| 31 Mar 20 | 103,546 | -3,544 | 42,250 | 2,194 |
| 31 Dec 19 | 102,531 | 1,442 | 41,891 | 2,233 |
| 30 Sep 19 | 99,622 | -5,226 | 40,801 | 2,155 |
| 30 Jun 19 | 95,312 | -7,547 | 40,165 | 2,168 |
| 31 Mar 19 | 91,624 | -6,294 | 38,959 | 2,113 |
| 31 Dec 18 | 91,776 | -7,509 | 38,903 | 2,172 |
| 30 Sep 18 | 84,709 | -4,999 | 39,183 | 2,316 |
| 30 Jun 18 | 83,805 | -5,439 | 39,267 | 2,333 |
| 31 Mar 18 | 79,307 | -4,851 | 38,753 | 2,102 |
| 31 Dec 17 | 76,843 | -6,079 | 37,441 | 1,785 |
| 30 Sep 17 | 78,791 | -4,083 | 36,843 | 1,433 |
| 30 Jun 17 | 78,558 | -4,117 | 36,431 | 1,374 |
| 31 Mar 17 | 82,414 | -2,985 | 36,486 | 1,535 |
| 31 Dec 16 | 83,385 | -618 | 36,705 | 1,566 |
| 30 Sep 16 | 83,370 | -1,497 | 36,006 | 1,840 |
| 30 Jun 16 | 80,930 | -238 | 35,042 | 1,801 |
| 31 Mar 16 | 78,773 | 487 | 34,379 | 1,722 |
| 31 Dec 15 | 76,945 | 256 | 34,544 | 1,732 |
| 30 Sep 15 | 75,648 | 2,214 | 34,732 | 1,527 |
| 30 Jun 15 | 75,489 | 3,232 | 33,581 | 1,738 |
| 31 Mar 15 | 74,776 | 542 | 33,640 | 1,913 |
| 31 Dec 14 | 73,018 | -527 | 32,627 | 2,250 |
| 30 Sep 14 | 74,742 | 1,037 | 31,354 | 2,399 |
| 30 Jun 14 | 73,309 | -2,572 | 32,043 | 2,310 |
| 31 Mar 14 | 71,882 | -2,577 | 30,836 | 1,791 |
| 31 Dec 13 | 70,695 | -3,068 | 30,299 | 1,910 |
| 30 Sep 13 | 69,835 | -4,568 | 30,422 | 1,785 |
| 30 Jun 13 | 69,432 | -3,098 | 32,029 | 1,357 |
Quality Earnings: A067290 is currently unprofitable.
Growing Profit Margin: A067290 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A067290 is unprofitable, and losses have increased over the past 5 years at a rate of 43.8% per year.
Accelerating Growth: Unable to compare A067290's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A067290 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A067290 has a negative Return on Equity (-227.45%), as it is currently unprofitable.